Cargando…

Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer

SIMPLE SUMMARY: Total thyroidectomy used to be recommended for all thyroid cancers. We now know that some thyroid cancers have a relatively low risk of recurrence. Today, for some of these cancers, depending on the type of tumor, its’ size and other tumor characteristics, a thyroid lobectomy (or hem...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartl, Dana M., Guerlain, Joanne, Breuskin, Ingrid, Hadoux, Julien, Baudin, Eric, Al Ghuzlan, Abir, Terroir-Cassou-Mounat, Marie, Lamartina, Livia, Leboulleux, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694652/
https://www.ncbi.nlm.nih.gov/pubmed/33171949
http://dx.doi.org/10.3390/cancers12113282
_version_ 1783615024633217024
author Hartl, Dana M.
Guerlain, Joanne
Breuskin, Ingrid
Hadoux, Julien
Baudin, Eric
Al Ghuzlan, Abir
Terroir-Cassou-Mounat, Marie
Lamartina, Livia
Leboulleux, Sophie
author_facet Hartl, Dana M.
Guerlain, Joanne
Breuskin, Ingrid
Hadoux, Julien
Baudin, Eric
Al Ghuzlan, Abir
Terroir-Cassou-Mounat, Marie
Lamartina, Livia
Leboulleux, Sophie
author_sort Hartl, Dana M.
collection PubMed
description SIMPLE SUMMARY: Total thyroidectomy used to be recommended for all thyroid cancers. We now know that some thyroid cancers have a relatively low risk of recurrence. Today, for some of these cancers, depending on the type of tumor, its’ size and other tumor characteristics, a thyroid lobectomy (or hemithyroidectomy) can be performed without increasing the patient’s risk of cancer recurrence. Thyroid lobectomy has the advantages of having less risk of surgical complications and a less frequent need for thyroid hormone replacement therapy. This approach is not optimal for all thyroid cancers, however, and careful tumor and patient selection are necessary. This review explains the rationale and criteria for patient selection for thyroid lobectomy for selected thyroid cancers. ABSTRACT: Many recent publications and guidelines have promoted a “more is less” approach in terms of treatment for low to intermediate risk differentiated thyroid cancer (DTC), which comprise the vast majority of thyroid cancers: less extensive surgery, less radioactive iodine, less or no thyroid hormone suppression, and less frequent or stringent follow-up. Following this approach, thyroid lobectomy has been proposed as a means of decreasing short- and long-term postoperative morbidity while maintaining an excellent prognosis for tumors meeting specific macroscopic and microscopic criteria. This article will examine the pros and cons of thyroid lobectomy for low to intermediate risk cancers and discuss, in detail, criteria for patient selection and oncological outcomes.
format Online
Article
Text
id pubmed-7694652
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76946522020-11-28 Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer Hartl, Dana M. Guerlain, Joanne Breuskin, Ingrid Hadoux, Julien Baudin, Eric Al Ghuzlan, Abir Terroir-Cassou-Mounat, Marie Lamartina, Livia Leboulleux, Sophie Cancers (Basel) Review SIMPLE SUMMARY: Total thyroidectomy used to be recommended for all thyroid cancers. We now know that some thyroid cancers have a relatively low risk of recurrence. Today, for some of these cancers, depending on the type of tumor, its’ size and other tumor characteristics, a thyroid lobectomy (or hemithyroidectomy) can be performed without increasing the patient’s risk of cancer recurrence. Thyroid lobectomy has the advantages of having less risk of surgical complications and a less frequent need for thyroid hormone replacement therapy. This approach is not optimal for all thyroid cancers, however, and careful tumor and patient selection are necessary. This review explains the rationale and criteria for patient selection for thyroid lobectomy for selected thyroid cancers. ABSTRACT: Many recent publications and guidelines have promoted a “more is less” approach in terms of treatment for low to intermediate risk differentiated thyroid cancer (DTC), which comprise the vast majority of thyroid cancers: less extensive surgery, less radioactive iodine, less or no thyroid hormone suppression, and less frequent or stringent follow-up. Following this approach, thyroid lobectomy has been proposed as a means of decreasing short- and long-term postoperative morbidity while maintaining an excellent prognosis for tumors meeting specific macroscopic and microscopic criteria. This article will examine the pros and cons of thyroid lobectomy for low to intermediate risk cancers and discuss, in detail, criteria for patient selection and oncological outcomes. MDPI 2020-11-06 /pmc/articles/PMC7694652/ /pubmed/33171949 http://dx.doi.org/10.3390/cancers12113282 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hartl, Dana M.
Guerlain, Joanne
Breuskin, Ingrid
Hadoux, Julien
Baudin, Eric
Al Ghuzlan, Abir
Terroir-Cassou-Mounat, Marie
Lamartina, Livia
Leboulleux, Sophie
Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
title Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
title_full Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
title_fullStr Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
title_full_unstemmed Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
title_short Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
title_sort thyroid lobectomy for low to intermediate risk differentiated thyroid cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694652/
https://www.ncbi.nlm.nih.gov/pubmed/33171949
http://dx.doi.org/10.3390/cancers12113282
work_keys_str_mv AT hartldanam thyroidlobectomyforlowtointermediateriskdifferentiatedthyroidcancer
AT guerlainjoanne thyroidlobectomyforlowtointermediateriskdifferentiatedthyroidcancer
AT breuskiningrid thyroidlobectomyforlowtointermediateriskdifferentiatedthyroidcancer
AT hadouxjulien thyroidlobectomyforlowtointermediateriskdifferentiatedthyroidcancer
AT baudineric thyroidlobectomyforlowtointermediateriskdifferentiatedthyroidcancer
AT alghuzlanabir thyroidlobectomyforlowtointermediateriskdifferentiatedthyroidcancer
AT terroircassoumounatmarie thyroidlobectomyforlowtointermediateriskdifferentiatedthyroidcancer
AT lamartinalivia thyroidlobectomyforlowtointermediateriskdifferentiatedthyroidcancer
AT leboulleuxsophie thyroidlobectomyforlowtointermediateriskdifferentiatedthyroidcancer